Summary
NGM Biopharmaceuticals (NGM) is a business focused on large markets with diseases driven by clear mechanisms-of-action. Led by a strong management team with a de-risked pipeline, NGM is a unique business model. NGM is a stock to monitor with a lead asset pursuing the ~$20 billion market of NASH and a substantial partnership with Merck that buffers NGM's balance sheet to complete multiple phase 2 studies.
The company was founded in 2007 by Jin-Long Chen, the company's chief scientific officer who was president up until 2014. Chen was the VP of Biology